Table 4 Univariate analysis of survival after surgery
Variables | MST (month) | Univariate analysis | P-value | |
|---|---|---|---|---|
HR | 95% CI | |||
Gender (male vs. female) | 62.4 vs. NA | 1.608 | 1.019–2.539 | 0.039 |
Pathology (adeno vs. mix) | 85.4 vs. 42.5 | 0.632 | 0.442–0.903 | 0.011 |
Blood transfusion (no vs. yes) | 12.4 vs. 81.8 | 0.262 | 0.156–0.440 | < 0.001 |
Surgical approaches (left thoracotomy vs. transhiatal) | 42.5 vs. 87.6 | 1.569 | 1.110–2.218 | < 0.001 |
Tumor size (≤ 4cm vs. >4cm) | NA vs. 43.8 | 0.41 | 0.274–0.616 | < 0.001 |
Adjuvant chemotherapy (no vs. yes) | 61.7 vs. 93.4 | 1.477 | 1.042–2.094 | 0.027 |
Postoperative hospital stays (≤ 10d vs. > 10d) | 59.9 vs. 99.7 | 0.806 | 0.680-0.956 | 0.012 |
Type of gastric resection (total vs. proximal) | 73.5 vs. 64.5 | 0.96 | 0.811–1.135 | 0.63 |
PNLNR | ||||
= 0 | NA | 0.403 | 0.298–0.543 | |
≤ 1 | 67.2 | 0.772 | 0.613–0.972 | |
> 1 | 11.8 | 1 | 1 | |
Perineuronal invasion (no vs. yes) | NA vs. 48.1 | 0.454 | 0.310–0.664 | < 0.001 |
Lymphovascular invasion (no vs. yes) | NA vs. 40.9 | 0.448 | 0.317–0.634 | < 0.001 |
Differentiation | 80 vs. 73 vs. 63 | 0.851 | ||
pTNM stage | < 0.001 | |||
I | 97.4 | 0.253 | 0.121–0.526 | |
II | 99.7 | 0.265 | 0.155–0.451 | |
III | 119.56 | 0.364 | 0.248–0.533 | |
IV | 24.5 | 1 | 1 | |
Serum CA199 (U/ml) (< 37 vs. ≥ 37) | 93.4 vs. 31.7 | 0.784 | 0.654–0.939 | 0.008 |
Serum CEA (ng/ml) (< 5 vs. ≥5) | 80.0 vs. 26.3 | 0.74 | 0.623–0.878 | < 0.001 |
Serum CA242 (U/ml) (< 20 vs. ≥20) | 73.0 vs. 12.0 | 0.746 | 0.596–0.934 | 0.01 |
Serum CA125 (U/ml) (< 35 vs. ≥35) | 71.4 vs. 70.1 | 0.605 | 0.423–0.866 | 0.004 |
Serum AFP (ng/ml) (< 10 vs. ≥10) | 80.3 vs. 51.1 | 1.067 | 0.761–1.496 | 0.706 |
Serum CA724 (U/ml) (< 6.9 vs. ≥6.9) | 70.1 vs. 80.0 | 0.862 | 0.715–1.039 | 0.117 |
Serum ferritin (ng/ml) (< 274.66 vs. ≥274.66) | 0.952 | 0.708–1.280 | 0.745 | |